Idecabtagene Vicleucel in Relapsed and Refractory Multiple Myeloma
2021 · New England Journal of Medicine · 2,258 citations
https://doi.org/10.1056/nejmoa2024850
N
Noopur Raje
Claim or correct this author profile
Claim this profile or suggest corrections to the name, affiliation, bio, photo, or paper titles. Approved changes appear as verified CitedEvidence overlays.
1.0K
Papers
44.1K
Citations
102
h-index
373
i10-index
Noopur Raje is an academic researcher from Boston Medical Center. The author has contributed to research in topics: Multiple Myeloma Research and Treatments & Protein Degradation and Inhibitors & CAR-T cell therapy research. The author has an h-index of 102, co-authored 871 publications.
ORCID: 0000-0003-3066-1275Papers by this author
worksAnti-BCMA CAR T-Cell Therapy bb2121 in Relapsed or Refractory Multiple Myeloma
2019 · New England Journal of Medicine · 1,675 citations
https://doi.org/10.1056/nejmoa1817226
Elranatamab in relapsed or refractory multiple myeloma: phase 2 MagnetisMM-3 trial results
2023 · Nature Medicine · 511 citations
https://doi.org/10.1038/s41591-023-02528-9
Treatment of relapsed and refractory multiple myeloma: recommendations from the International Myeloma Working Group
2021 · The Lancet Oncology · 257 citations
https://doi.org/10.1016/s1470-2045(20)30756-7
Monitoring, prophylaxis, and treatment of infections in patients with MM receiving bispecific antibody therapy: consensus recommendations from an expert panel
2023 · Blood Cancer Journal · 157 citations
https://doi.org/10.1038/s41408-023-00879-7
A novel role for CCL3 (MIP-1α) in myeloma-induced bone disease via osteocalcin downregulation and inhibition of osteoblast function
2011 · Leukemia · 151 citations
https://doi.org/10.1038/leu.2011.43
Research topics
topicsChat about Author
Papers
Chat
Click to start Chat